FindTrial
Sign In

Anvumetostat

DRUG5 trials

Sponsors

Amgen

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersAdvanced MTAP-null Solid TumorsMTAP-deleted NSCLCMTAP-null Non-Small-Cell Lung CancerMTAP-null Solid TumorsNon-small Cell Lung CancerThoracic Tumors

Phase 1

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Active, not recruitingNCT05094336
AmgenAdvanced MTAP-null Solid Tumors
Start: 2022-02-01End: 2028-05-29Updated: 2026-03-31
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
CompletedNCT05975073
AmgenMTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
Start: 2023-08-01End: 2026-03-26Updated: 2026-04-22
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
RecruitingNCT06333951
AmgenNon-small Cell Lung Cancer, Thoracic Tumors
Start: 2024-09-17End: 2031-10-27Target: 500Updated: 2026-04-13
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
RecruitingNCT06360354
AmgenAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Start: 2024-05-29End: 2029-02-25Target: 350Updated: 2026-03-31

Phase 2

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
RecruitingNCT06593522
AmgenMTAP-deleted NSCLC
Start: 2024-12-26End: 2030-11-29Target: 200Updated: 2026-04-07

Related Papers

Abstract 7065: Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor.
Cancer Research2026-04-03
Abstract 4268: The allosteric MAT2A inhibitor IDE397 uniquely exploits metabolic liabilities associated with MTAP deletion to perturb DNA replication and repair
Cancer Research2025-04-211 citations
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.
2025-01-0618 citations
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers.
2025-01-0412 citations
Abstract B177: The discovery and preclinical characterization of AMG 193, a first-in-class MTA-cooperative PRMT5 inhibitor with broad activity against <i>MTAP</i>-null cancers
Molecular Cancer Therapeutics2023-12-015 citations
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
Journal of Clinical Oncology2022-06-0110 citations